0000000000848729

AUTHOR

Rosaria Gesuita

showing 3 related works from this author

Sclerostin and antisclerostin antibody serum levels predict the presence of axial spondyloarthritis in patients with inflammatory bowel disease

2018

Objective.The early diagnosis of inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA/IBD) in patients affected by IBD represents a major topic in clinical practice; in particular, to date there are no available serum biomarkers revealing the presence of joint inflammation in these patients. Sclerostin (SOST), an antagonist of the Wnt/β-catenin pathway, and antisclerostin-immunoglobulin G (anti-SOST–IgG) have been recently studied in patients with ankylosing spondylitis (AS) as a putative marker of disease activity.Methods.SOST and anti-SOST-IgG serum levels were assayed in 125 patients with IBD, 85 with axial or peripheral SpA, and in control groups (patients with AS and rheu…

0301 basic medicineMaleAntibodieAntigen-Antibody ComplexInflammatory bowel diseaseGastroenterologyPathogenesischemistry.chemical_compound0302 clinical medicineGenetic MarkerImmunology and AllergyProspective StudiesMultivariate AnalysibiologyWnt signaling pathwayMiddle AgedRheumatoid arthritisBone Morphogenetic ProteinsRegression AnalysisFemalemedicine.symptomAntibodyHumanGenetic MarkersAdultmedicine.medical_specialtySclerostinImmunologyInflammationAntibodiesRegression AnalysiStatistics Nonparametric03 medical and health sciencesRheumatologyInternal medicineSpondyloarthritismedicineHumansSpondylitis AnkylosingAdaptor Proteins Signal TransducingAntisclerostin Antibodie030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryBone Morphogenetic ProteinInflammatory Bowel DiseaseBiomarkerInflammatory Bowel Diseasesmedicine.diseaseProspective StudieSettore MED/16 - Reumatologia030104 developmental biologychemistryROC CurveImmunoglobulin GMultivariate Analysisbiology.proteinSclerostinSpondyloarthritibusinessBiomarkers
researchProduct

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison

2015

AimsImproving glycaemic control in people with Type1 diabetes is known to reduce complications. Our aim was to compare glycaemic control among people with Type1 diabetes using data gathered in regional or national registries. MethodsData were obtained for children and/or adults with Type1 diabetes from the following countries (or regions): Western Australia, Austria, Denmark, England, Champagne-Ardenne (France), Germany, Epirus, Thessaly and Thessaloniki (Greece), Galway (Ireland), several Italian regions, Latvia, Rotterdam (The Netherlands), Otago (New Zealand), Norway, Northern Ireland, Scotland, Sweden, Volyn (Ukraine), USA and Wales) from population or clinic-based registries. The sampl…

MaleDenmarkEndocrinology Diabetes and Metabolismmetabolic-controlregistryEndocrinologyGermanyInsulinMedicineadolescentsRegistriesYoung adultNetherlandseducation.field_of_studyGreeceNorway18 countriesClinical PracticeEnglandItalyAustriaPractice Guidelines as TopicFemaleFranceGuideline AdherenceUkraineAdultcomplicationsAdolescentPopulationNorthern IrelandNorthern irelandAge and sexYoung AdultInsulin Infusion SystemschildrenDiabetes mellitusInternal MedicineHumansHypoglycemic AgentscareeducationchildhoodGlycated HemoglobinSwedenType 1 diabetesWalesbusiness.industryWestern Australiamedicine.diseaseLatviaiddmUnited StatesDiabetes Mellitus Type 1ScotlandSample size determinationOptometrybusinessIrelandNew ZealandDemographyDiabetic Medicine
researchProduct

A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease

2007

BACKGROUND: Treatment of celiac disease (CD) is based on the avoidance of gluten-containing food. However, it is not known whether trace amounts of gluten are harmful to treated patients. OBJECTIVE: The objective was to establish the safety threshold of prolonged exposure to trace amounts of gluten (ie, contaminating gluten). DESIGN: This was a multicenter, double-blind, placebo-controlled, randomized trial in 49 adults with biopsy-proven CD who were being treated with a gluten-free diet (GFD) for > or =2 y. The background daily gluten intake was maintained at < 5 mg. After a baseline evaluation (t0), patients were assigned to ingest daily for 90 d a capsule containing 0, 10, or 50 mg glute…

AdultMaleGluten free diet Celiac Diseasemedicine.medical_specialtyGlutensPlacebo-controlled studyMedicine (miscellaneous)gastroenterologyDiseasedigestive systemGastroenterologyCoeliac diseaselaw.inventionRandomized controlled trialDouble-Blind Methodgluten-free dietlawInternal medicineImmunopathologyIntestine SmallMedicineHumansgluten toxicitysmall-intestinal morphometryLymphocyte CountProspective StudiesIntestinal MucosaProspective cohort studyAutoantibodiesceliac disease; gastroenterology; gluten threshold in gluten-free food; gluten threshold in gluten-free food.; gluten toxicity; gluten-free diet; small-intestinal morphometrychemistry.chemical_classificationNutrition and DieteticsDose-Response Relationship Drugbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseGlutendigestive system diseasesgluten threshold in gluten-free foodchemistryToxicityFemalebusinessceliac disease
researchProduct